Alkermes plc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (40)

Latest Posts

About This Stock More About This Stock
Alkermes Downgraded To Sell From Neutral At Goldman Sachs
Article By: The Fly
Thursday, July 30, 2020 6:05 AM EDT
Goldman Sachs analyst Terence Flynn downgraded Alkermes to Sell from Neutral with a price target of $15, down from $19.
In this article: ALKS
Alkermes Targets Bipolar Disorder And Schizophrenia
Article By:
Sunday, February 16, 2020 11:52 AM EDT
We strongly recommend that investors take advantage of the weakness and buy Alkermes, whose treatment of schizophrenia and bipolar disorder has been accepted by the FDA for review.
In this article: ALKS Also: BIIB, MYL
Key FDA Events In June Investors Need To Watch Out For
Article By: Zacks Investment Research
Sunday, June 3, 2018 12:49 PM EDT
It has been a busy year for the FDA so far with the agency approving 14 drugs. The approval of these drugs should boost their respective companies’ top line as a few of them are struggling with decline in sales of legacy drugs.
In this article: MRK, VRX, ARRY, GWPH, ALKS, AKAO
Analyst Cuts Alkermes Rating As Cancer Drug Seems Less Effective Than Competitor
Article By: The Fly
Thursday, February 22, 2018 2:44 PM EDT
Shares of Alkermes are sliding after Jefferies analyst Biren Amin downgraded the stock to Hold as he believes the shares are fairly valued.
In this article: ALKS Also: NKTR
Alkermes Rises After Nektar Said To Explore Sale
Article By: The Fly
Friday, February 2, 2018 4:12 PM EDT
Shares of Alkermes have been rising this afternoon after Bloomberg reported that another drugmaker exploring some of the same therapeutic areas, Nektar Therapeutics, is exploring its strategic options, including a potential sale.
In this article: ALKS, NKTR


Latest Tweets for $ALKS

No tweets yet!